Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
UK Dementia Research Institute at UCL, London, UK.
Mol Psychiatry. 2020 Nov;25(11):2919-2931. doi: 10.1038/s41380-019-0410-8. Epub 2019 Apr 12.
Familial Alzheimer's disease (fAD) mutations alter amyloid precursor protein (APP) cleavage by γ-secretase, increasing the proportion of longer amyloidogenic amyloid-β (Aβ) peptides. Using five control induced pluripotent stem cell (iPSC) lines and seven iPSC lines generated from fAD patients, we investigated the effects of mutations on the Aβ secretome in human neurons generated in 2D and 3D. We also analysed matched CSF, post-mortem brain tissue, and iPSCs from the same participant with the APP V717I mutation. All fAD mutation lines demonstrated an increased Aβ42:40 ratio relative to controls, yet displayed varied signatures for Aβ43, Aβ38, and short Aβ fragments. We propose four qualitatively distinct mechanisms behind raised Aβ42:40. (1) APP V717I mutations alter γ-secretase cleavage site preference. Whereas, distinct presenilin 1 (PSEN1) mutations lead to either (2) reduced γ-secretase activity, (3) altered protein stability or (4) reduced PSEN1 maturation, all culminating in reduced γ-secretase carboxypeptidase-like activity. These data support Aβ mechanistic tenets in a human physiological model and substantiate iPSC-neurons for modelling fAD.
家族性阿尔茨海默病(fAD)突变通过 γ-分泌酶改变淀粉样前体蛋白(APP)的切割,增加了更长的淀粉样β(Aβ)肽的比例。使用五个对照诱导多能干细胞(iPSC)系和七个来自 fAD 患者的 iPSC 系,我们研究了突变对在 2D 和 3D 中生成的人神经元中的 Aβ 分泌组的影响。我们还分析了具有 APP V717I 突变的相同参与者的匹配 CSF、死后脑组织和 iPSC。所有 fAD 突变系与对照相比均显示出 Aβ42:40 比值增加,但 Aβ43、Aβ38 和短 Aβ 片段的特征各不相同。我们提出了导致 Aβ42:40 升高的四种不同的定性机制。(1)APP V717I 突变改变了 γ-分泌酶切割位点偏好。然而,不同的早老素 1(PSEN1)突变导致(2)γ-分泌酶活性降低,(3)蛋白稳定性改变或(4)PSEN1 成熟减少,所有这些都导致 γ-分泌酶羧肽酶样活性降低。这些数据支持人类生理模型中的 Aβ 机制原则,并证实 iPSC 神经元可用于建模 fAD。